Modified AAV Capsid Enhances Cochlear Infection Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inner ear gene therapy methods using adeno-associated viral vectors (AAV) have low infection efficiency in cochlear cells, limiting their effectiveness in treating hearing loss.
Innovation Solution
A recombinant AAV comprising a modified AAV capsid protein with mutations in amino acids 587-595 of AAV8-VP1 is used to enhance infection efficiency in the cochlear lateral wall, specifically targeting marginal cells of the stria vascularis, thereby delivering genetic material to reduce hearing loss and dizziness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV vectors are used for inner ear gene therapy, then the therapy can be administered, but infection efficiency in cochlear cells remains low
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the AAV capsid protein (specifically in the VP1 region). This structural parameter modification enables the viral vector to efficiently infect cochlear lateral wall cells including marginal cells, thereby resolving the contradiction between reliable administration and effective infection.
2Reliability
If AAV-mediated gene therapy is applied to improve auditory function, then hearing loss treatment is achieved, but infection rates in some cochlear cell types are low
Solution Approach 1:
The patent applies local quality by creating a specialized capsid variant (AAV8BP2) with specific amino acid modifications that confer enhanced affinity for cochlear lateral wall cells. This localized optimization of the viral vector properties enables selective and efficient infection of target cells while maintaining safety for other cell types.
3Productivity
If higher infection efficiency is achieved through viral vector modification, then gene delivery effectiveness improves, but vector complexity increases
Solution Approach 1:
The patent applies segmentation by focusing modifications on a specific segment of the capsid protein (the VP1 region, particularly amino acids 587-595). This targeted approach allows the rest of the viral vector structure to remain simple and well-characterized, while only the necessary functional segment is modified to achieve enhanced cochlear cell infection.
Data Source
AI summary
Provided herein are adeno-associated viruses and methods for using same to treat or prevent disorders that affect the inner ear of a subject.